370 related articles for article (PubMed ID: 29309202)
1. Alemtuzumab for the treatment of multiple sclerosis.
Evan JR; Bozkurt SB; Thomas NC; Bagnato F
Expert Opin Biol Ther; 2018 Mar; 18(3):323-334. PubMed ID: 29309202
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.
Wang L; Qi CH; Zhong R; Yuan C; Zhong QY
Medicine (Baltimore); 2018 Feb; 97(8):e9908. PubMed ID: 29465579
[TBL] [Abstract][Full Text] [Related]
3. [Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab].
Eichau S; Lopez-Ruiz R; Ruiz-Pena JL; Paramo MD; Navarro-Mascarell G; Izquierdo G
Rev Neurol; 2018 Jun; 66(11):395-396. PubMed ID: 29790573
[TBL] [Abstract][Full Text] [Related]
4. Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis.
John N; Carroll A; Brownlee WJ; Chataway J
J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1376-1378. PubMed ID: 31079064
[No Abstract] [Full Text] [Related]
5. Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis.
Kashani N; Kelland EE; Vajdi B; Anderson LM; Gilmore W; Lund BT
Front Immunol; 2021; 12():706278. PubMed ID: 34777337
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract][Full Text] [Related]
7. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis.
Buonomo AR; Zappulo E; Viceconte G; Scotto R; Borgia G; Gentile I
Expert Opin Drug Saf; 2018 Jul; 17(7):709-717. PubMed ID: 29848085
[TBL] [Abstract][Full Text] [Related]
8. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
9. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.
Federle L; Puthenparampil M; Stenta G; Paolo G; Francesco P
Mult Scler Relat Disord; 2019 May; 30():262-264. PubMed ID: 30851640
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Arroyo González R; Kita M; Crayton H; Havrdova E; Margolin DH; Lake SL; Giovannoni G;
Mult Scler; 2017 Sep; 23(10):1367-1376. PubMed ID: 27885061
[TBL] [Abstract][Full Text] [Related]
12. Current evaluation of alemtuzumab in multiple sclerosis.
Coyle PK
Expert Opin Biol Ther; 2014 Jan; 14(1):127-35. PubMed ID: 24289293
[TBL] [Abstract][Full Text] [Related]
13. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
Fernández Ó
Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
[TBL] [Abstract][Full Text] [Related]
14. Development of Autoimmune Thyroid Disease in Multiple Sclerosis Patients Post-Alemtuzumab Improves Treatment Response.
Sovetkina A; Nadir R; Scalfari A; Tona F; Murphy K; Rigoni E; Dorsey R; Malik O; Nandoskar A; Singh-Curry V; Nicholas R; Martin N
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32667988
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis.
Syed YY
Drugs; 2021 Jan; 81(1):157-168. PubMed ID: 33367970
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Perumal JS; Foo F; Cook P; Khan O
Mult Scler; 2012 Aug; 18(8):1197-9. PubMed ID: 22252465
[TBL] [Abstract][Full Text] [Related]
17. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
[TBL] [Abstract][Full Text] [Related]
18. A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience.
Alroughani R; AlMojel M; Al-Hashel J; Ahmed SF
Mult Scler Relat Disord; 2023 Jun; 74():104712. PubMed ID: 37054581
[TBL] [Abstract][Full Text] [Related]
19. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
[TBL] [Abstract][Full Text] [Related]
20. The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies.
Baker D; Ali L; Saxena G; Pryce G; Jones M; Schmierer K; Giovannoni G; Gnanapavan S; Munger KC; Samkoff L; Goodman A; Kang AS
Front Immunol; 2020; 11():124. PubMed ID: 32117274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
